MX2012004610A
MX355971B
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent.
|
CA2814958A
CA2814958C
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
MYPI2012001764A
MY166634A
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
PE2012000530A
PE20121709A1
(en)
|
2009-10-22 |
2010-10-22 |
A PHARMACEUTICAL COMPOSITION TO TREAT CANCER INCLUDING TRYPSINOGEN AND / OR CHEMOTRIPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VAINILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCING AGENT
|
DK16174383.6T
DK3095458T3
(en)
|
2009-10-22 |
2010-10-22 |
PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT INCLUDING TRYPSINOGEN AND CHYMOTRYPSINOGEN
|
CN201710885368.4A
CN107625957B
(en)
|
2009-10-22 |
2010-10-22 |
Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
|
EP16174383.6A
EP3095458B1
(en)
|
2009-10-22 |
2010-10-22 |
Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
|
PT16174383T
PT3095458T
(en)
|
2009-10-22 |
2010-10-22 |
Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
|
JP2012534496A
JP5871805B2
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen.
|
BR112012009521-8A
BR112012009521B1
(en)
|
2009-10-22 |
2010-10-22 |
PHARMACEUTICAL COMPOSITION AND USE OF CHYMOTRIPSINOGEN AND TRIPSINOGEN
|
RU2012120785/15A
RU2012120785A
(en)
|
2009-10-22 |
2010-10-22 |
PHARMACEUTICAL COMPOSITIONS
|
NZ599996A
NZ599996A
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
TR2018/15315T
TR201815315T4
(en)
|
2009-10-22 |
2010-10-22 |
Pharmaceutical composition comprising trypsinogen and chymotrypsinogen for the treatment of cancer.
|
EP10824316A
EP2490711A4
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
SG10201406651PA
SG10201406651PA
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
|
KR1020127012943A
KR101936439B1
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
CN201080054056.5A
CN102639145B
(en)
|
2009-10-22 |
2010-10-22 |
Comprising trypsinogen and/or chymotrypsinogen and selected from selenium compound, class vanillic aldehyde compound and cytoplasm glycolysis reduce the pharmaceutical composition for being used to treat cancer of the activating agent of agent
|
ES16174383.6T
ES2692377T3
(en)
|
2009-10-22 |
2010-10-22 |
Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
|
PCT/AU2010/001403
WO2011047434A1
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
AU2010310887A
AU2010310887B9
(en)
|
2009-10-22 |
2010-10-22 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
US13/502,917
US9636359B2
(en)
|
2009-10-22 |
2010-10-22 |
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
IL219216A
IL219216A
(en)
|
2009-10-22 |
2012-04-16 |
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
CL2012001019A
CL2012001019A1
(en)
|
2009-10-22 |
2012-04-20 |
Pharmaceutical composition comprising a protease proenzyme selected from at least trypsinogen and chymotrypsinogen and an active agent selected from at least one selenium compound, a vanilloid compound, a cytoplasmic glycolysis reducing agent and optionally a glycosidohydrolase; and use to treat cancer.
|
ZA2012/03689A
ZA201203689B
(en)
|
2009-10-22 |
2012-05-21 |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a sytoplasmic glycolysis reduction agent
|
US15/462,655
US10350239B2
(en)
|
2009-10-22 |
2017-03-17 |
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
|
HK18108670.0A
HK1249017A1
(en)
|
2009-10-22 |
2018-07-04 |
A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
|
US16/428,581
US20190388463A1
(en)
|
2009-10-22 |
2019-05-31 |
Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent
|
US17/862,120
US20230137573A1
(en)
|
2009-10-22 |
2022-07-11 |
Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent
|